The Centre d’Investigation Clinique en Biothérapies (CBT-510) was created in 2005 by Inserm, Aix-Marseille University, IPC and AP-HM, following a call jointly published by Inserm, the DHOS division at the French Ministry of Health and several other partners interested in the development and validation of innovative biological therapies.
The project places a strong emphasis on sharing experience in cell and tissue engineering, clinical-grade and scale technique validations, development of biological assays used to evaluate the potency of cell therapy products and products of tissue engineering, or to evaluate efficiency and safety in patients (surrogate markers), and knowledge and compliance with fast evolving regulatory aspects.
The CBT-510 associates the cell therapy facility (“Centre de Thérapie Cellulaire et Génique”, CTCG;) at IPC for oncology, with the cell and tissue engineering facility (“Laboratoire de Culture et de Thérapie Cellulaire”, LCTC) at Hôpital de la Conception for other medical fields.
The CBT 510 was evaluated by AERES in 2010, and funded again following this evaluation..
The procedure to request access to biological samples is indicated on the Biobank page.
Management & contact: Pr Christian Chabannon
Date of creation: 2005
Location: IPC and AP-HM
Staff (CRCM and others): 5 MD, 3 PharmD, 2 Scientists, 1 Engineer, 4 technicians